A downtrend has been apparent in Supernus Pharmaceuticals (SUPN) lately with too much selling pressure. The stock has ...

NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Atria Investments Inc bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) in the 4th quarter, HoldingsChannel.com reports. The fund bought 7,978 shares of the specialty ...

We recently compiled a list of the 10 Cash-Rich Small Cap Stocks To Invest In According To Analysts. In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc.

StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy rating in a report published on Sunday morning. Separately, Cantor Fitzgerald ...

Highlights,Smartleaf Asset Management LLC increased its stake in Supernus Pharmaceuticals, reflecting growing institutional ...

Ritz-Carlton South Beach, Miami, Fla. Investors interested in arranging a meeting with the Company's management during these conferences should contact the respective conference coordinators.

A downtrend has been apparent in Supernus Pharmaceuticals (SUPN) lately with too much selling pressure. The stock has declined 20.1% over the past four weeks. However, given the fact that it is ...

About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS ...